The positive report just released by Zacks Small-Cap Research on FluoroPharma Medical, developer of advanced medical diagnostic imaging tracer products for use with positron emission tomography (PET), highlights the principal advantages of FluoroPharma in the healthcare market. Although healthcare itself is a steadily rising sea, with aging baby boomers continuing to feed the market, the distinctive advantages of FluoroPharma give the company a unique edge.
FluoroPharma is developing specialized tracer chemicals that are able to integrate themselves into subtle bodily processes, allowing sophisticated PET technology to detect biological events at the cellular and molecular level, long before the manifestation of disease symptoms. As such, PET technology represents an internal detection resolution unmatched by other diagnostic imaging approaches, and FluoroPharma’s focus on PET provides the company’s first key advantage in the healthcare marketplace.
In addition, FluoroPharma’s main radiopharmaceutical products target the extensive coronary artery disease (CAD) market. CAD remains a major global killer and is the subject of massive funding for the development of associated products. FluoroPharma has three tracer products directly related to CAD. CardioPET helps identify patients that will benefit from PCI or revascularization and guide intervention, and can evaluate CAD in patients that cannot go through stress tests. BFPET can be used for the detection of presumptive CAD in combination with stress testing, as well as for the improved detection of CAD related to multi-vessel disease. VasoPET can be used for evaluating patients experiencing Acute Coronary Syndrome or a risk of stroke, or for evaluating therapy following an acute cardiac event or stroke.
Yet another advantage for FluoroPharma is the unmatched capabilities of their particular tracers. Current CAD related PET tracers carry an unusually high cost, and have also experienced safety issues and availability shortages. As a result, there is a significant demand for new approaches, as offered by FluoroPharma.
For more information, see the company website at www.FluoroPharma.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
